U.S. Stock Night Market Movements
Spero Therap rose 27.49% in the night market. Based on recent key news:
<ol>
<li>
On June 17, Spero Therapeutics announced that its oral antibiotic Utebzi received approval from the U.S. FDA for the treatment of complicated urinary tract infections. This drug is the first approved oral carbapenem antibiotic and is expected to be launched in the U.S. by the end of 2026. This news drove up Spero's stock price.
</li>
<li>
On June 18, the FDA approval news further confirmed Utebzi's market potential, especially in treating infections caused by multidrug-resistant pathogens. This news boosted investor confidence, leading to a significant increase in stock price.
</li>
<li>
On June 18, the collaboration agreement between GSK and Spero ensured global exclusive licensing for Utebzi (excluding Japan and certain parts of Asia), further solidifying Spero's position in the anti-infective drug market and driving up stock prices. The demand for anti-infective drugs is strong, with noticeable capital inflow.
</li>
</ol>
Stocks with High Trading Volume in the Industry
ELTX fell 15.07% in the night market. Based on recent key news:
<ol>
<li>
On June 17, Elicio Therapeutics announced that its ELI-002 7P vaccine failed to prevent disease recurrence in pancreatic cancer patients, causing the stock price to plummet 14.67% during trading. The company plans to conduct a Phase 1 trial to evaluate the effects of combination chemotherapy and anti-PD-1 drugs. Source: Benzinga
</li>
<li>
On June 15, Elicio Therapeutics' Phase 2 trial did not meet the expected primary endpoint for disease-free survival, leading to a 72% drop in stock price. The company plans to focus on R0 resected patients in Phase 3 and increase the dosage of ELI-002 7P. Source: Reuters
</li>
<li>
On June 16, analyst Jones Trading downgraded Elicio Therapeutics' rating to hold, further undermining market confidence. Source: Benzinga The biotechnology industry has been highly volatile recently and requires attention.
</li>
</ol>
Moderna rose 0.50% in the night market. Based on recent key news:
<ol>
<li>
On June 16, U.S. FDA staff indicated that Moderna's flu vaccine mFlusiva showed a strong immune response in adults aged 65 and older, potentially supporting its efficacy. This news drove Moderna's stock price up by 2.5%.
</li>
<li>
On June 17, Moderna's stock price rose 1.19% in pre-market trading, reaching $56.06. This increase was mainly influenced by expectations of the FDA soon approving its flu vaccine
On June 18, Moderna plans to invest in production facilities in Germany and intends to acquire the factory that BioNTech plans to close. This news caused Moderna's stock price to rise by about 12%. Moderna expects to launch multiple new products in 2027 and 2028.
</li>
</ol>
BeiGene's stock rose 2.94% in after-hours trading. Based on recent key news:
<ol>
<li>
On June 15, UBS analysts maintained a buy rating on BeOne Medicines and set a target price of HKD 279. This move boosted market confidence in the company, driving the stock price up.
</li>
<li>
On June 16, BeOne Medicines AG submitted a preliminary beneficial ownership declaration, appointing Elizabeth Fisher Mooney as a director. This news may be interpreted by the market as a positive change in the company's governance structure, further supporting the stock price.
</li>
<li>
On June 16, Benzinga reported on insider trading activities at BeOne Medicines, indicating ongoing market interest in the company's stock, which may affect investor sentiment. The pharmaceutical industry has performed strongly recently, with significant capital inflows
</li>
</ol>

SPRO

Spero Therap rose 27.49% in after-hours trading; Elicio Therapeutics fell 15.07% in after-hours trading, with a trading volume of USD 445,300; Moderna rose 0.50% in after-hours trading, with a trading volume of USD 438,700; BeiGene rose 2.94% in after-hours trading, with a trading volume of USD 222,200

Price Alert

U.S. stock night market volatility: Spero surged 27.49% in after-hours trading! Oral antibiotics approved, GSK backing ignites funding